TY - T1的效果如何是BCNU复发胶质母细胞瘤在现代?摩根富林明首页-神经学乔-神经病学SP - 1281 LP - 1284——10.1212/01. wnl.0000140495.33615。CA六世- 63 - 7 AU - a . a . Brandes AU - a . Tosoni盟- p . Amista AU - l . Nicolardi AU - d·格罗索盟- f·迪盟- m . Ermani Y1 - 2004/10/12 UR - //www.ez-admanager.com/con首页tent/63/7/1281.abstract N2 -背景:最初的研究进行了亚硝基脲在30年前。这些药物仍然胶质母细胞瘤的标准化疗。然而,由于亚硝基脲的标准用来评估活动在neuro-oncologic环境已经改变,新的数据在他们的活动是必要的。方法:作者进行了一项II期研究40例手术后复发胶质母细胞瘤和标准的放射治疗。他们在6个月无进展生存分析(PFS-6)、时间(TTP)进展,反应率和毒性。病人服用80 mg / m2卡莫司汀天1到3,每8周最多6个周期。结果:TTP中位数为13.3周(95% CI, 10.26 - 16.86周),和PFS-6为17.5% (95% CI, 8.9 - 34.3)。化疗反应,年龄≤40年,和性能状态≥90 TTP的重要预后因素; however, with multivariate analysis, only response to chemotherapy was significant. The major side effects were reversible hematologic and long-lasting hepatic and pulmonary toxicity. Conclusion: The activity of this BCNU regimen is comparable with that reported in the past and with the newest therapies, such as temozolomide. However, BCNU toxicity is high and recovery is slow, thus compromising the administration of further drugs in patients with progressive disease. ER -